About this medicine

Alprazolam is a benzodiazepine. The checked UK Xanax tablets are for brief treatment of severe anxiety, not an imported US panic-disorder or extended-release regimen. A product-information record establishes the labelled product, not whether a local pharmacy has stock; a manufacturer supply notice is also present.

What is this medicine used for?

The UK indication is short-term symptomatic anxiety in adults when severe, disabling or causing extreme distress. The current SmPC specifies the lowest effective dose for a maximum of 2–4 weeks, with frequent reassessment. This is not a general licence for insomnia or stand-alone treatment of depression.

Which warning signs need help?

Opioids, alcohol and other sedatives can add dangerous respiratory depression. Slow or difficult breathing, inability to wake, collapse, seizure, severe allergy or suspected overdose needs immediate medical help. Abrupt discontinuation after regular use can cause severe withdrawal, including seizures; do not suddenly stop on your own.

How do I take it safely?

UK reference dosing for anxiety is 0.25–0.5 mg three times daily, with a usual stated ceiling of 3 mg/day. Older or debilitated adults start lower. These are product facts, not a personal schedule; the prescriber determines dose, duration and a plan for safe discontinuation.

What side effects should I know about?

Drowsiness, dizziness, poor coordination, memory difficulties and slurred speech can occur. Report excessive sedation, falls, jaundice or troublesome mental-state changes. Avoid hazardous activities when affected. A new symptom should prompt review, not an assumption that a higher dose is needed.

Who needs extra care with this medicine?

The checked product is contraindicated in myasthenia gravis, severe respiratory insufficiency, sleep apnoea and severe liver impairment. Depression, self-harm risk, previous substance-use problems, falls and kidney or less severe liver disease require assessment. It is not a stand-alone treatment for depression.

Can it affect my other medicines?

Azole antifungals and other CYP3A4 inhibitors may greatly increase exposure; macrolide antibiotics, fluvoxamine and ritonavir need medicine-specific review. Ritonavir's effect changes with treatment duration, so a simple universal rule is unsafe. Digoxin concentrations can rise, especially in older people. Check all sedating products together.

What check-ups will I need?

Agree review dates and an ending strategy before treatment. Monitor benefit, sedation, falls, mood, alcohol or opioid combinations, tolerance and problems controlling use. Reduced effect is a reason for reassessment, not self-escalation. People experiencing withdrawal need support without being automatically labelled addicted.

What about pregnancy, breastfeeding and age?

Under-18 safety and efficacy are not established. Pregnancy use requires a clear clinical need; late exposure may cause newborn sedation, breathing or muscle-tone problems and withdrawal. Breastfeeding is not recommended in the checked information. Do not abruptly stop established treatment on discovering a pregnancy.

What if I miss a dose or want to stop?

A missed dose may be taken when remembered unless the next is due; never double it. Stopping requires an individual, gradual plan. MHRA advises adapting reductions to the person's response, sometimes over weeks or months; a fixed rapid taper is not appropriate for everyone.

How does it work?

Alprazolam strengthens the effect of GABA, a chemical messenger that helps restrain activity in the brain. At a connection between nerve cells, GABA attaches to a receiving protein called the GABA-A receptor and makes the next cell less likely to send an electrical signal. Alprazolam attaches to a different part of that receptor, called the benzodiazepine site, and increases the response to the GABA already present.

This increase in inhibition, meaning restraint on nerve-cell activity, can ease anxiety. The same receptor system is involved in attention, memory and movement, which helps explain why the medicine can also cause sleepiness or poorer coordination. Feeling calmer is an effect of the medicine; it does not establish that all the causes of a person’s distress have been resolved.

How does it affect my body?

Sedation, impaired memory and unsteadiness can affect driving and falls risk. Occasionally agitation, aggression or other paradoxical behavioural changes occur instead of calm. Physical dependence can develop during prescribed use; it is not synonymous with addiction and deserves a non-judgemental discussion.

How does my body process it?

Peak blood concentrations occur after about one to two hours; the checked UK mean half-life is 12–15 hours. CYP3A4-related metabolism makes interactions important. Older age and organ impairment can prolong exposure, so repeated doses may accumulate even without a recent dose increase.

How do treatment options differ?

NICE limits benzodiazepines for generalised anxiety to short crisis use and does not recommend them for panic disorder. This differs from some US alprazolam indications. Psychological treatments and other medicines have different roles; regulatory permission, guideline preference and local NHS access are distinct.

A closer look at the science

It binds at benzodiazepine sites in the brain rather than replacing GABA. The same active molecule can appear in different pharmaceutical formulations, but formulation changes alter delivery; this UK article does not provide a conversion to US Xanax XR or dissolving products.

How was this medicine developed?

The checked UK Xanax record gives first authorisation on 27 August 1982. Its September 2026 revision sits alongside MHRA's January 2026 strengthened class warnings. These UK warnings should be described as UK safety information, not relabelled FDA boxed warnings.

Sources and References

  1. Xanax 250 microgram tablets: SmPC

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom; NHS policy implementation varies by nation.

  2. Xanax 500 microgram tablets: SmPC

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom; NHS policy implementation varies by nation.

  3. Xanax 250 and 500 microgram tablets: patient leaflet

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom; NHS policy implementation varies by nation.

  4. Improving information supplied with gabapentinoids, benzodiazepines and z-drugs

    Scope: United Kingdom; NHS policy implementation varies by nation.

  5. NICE CG113: Generalised anxiety disorder and panic disorder

    Scope: United Kingdom; NHS policy implementation varies by nation.

  6. NICE CG113: What treatments should I be offered for panic disorder?

    Scope: United Kingdom; NHS policy implementation varies by nation.

  7. Xanax: UK product information and supply notice

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom; NHS policy implementation varies by nation.

  8. Benzodiazepines: medicines and risks of addiction, dependence and withdrawal

    Scope: United Kingdom.

  9. Xanax immediate-release: current prescribing information — mechanism explanation

    Scope: Mechanism explanation only. Source sections checked: 12.1 Mechanism of Action; 12.3 Pharmacokinetics; 9.3 Dependence. This does not establish UK product authorisation or prescribing..

  10. Alprazolam: MedlinePlus Drug Information — mechanism explanation

    Scope: Mechanism explanation only. Source sections checked: How should this medicine be used?; Important warning. This does not establish UK product authorisation or prescribing..

  11. All Opioid Pain Medicines: Drug Safety Communication - FDA Updates Prescribing Information to Provide Additional Guidance for Safe Use | FDA
  12. New Safety Measures Announced for Opioid Analgesics, Prescription Opioid Cough Products, and Benzodiazepines | FDA

Was this article helpful?

Was this article helpful?

Sends your choice, article identifier, edition and optional issue to Psychiatry Atlas. No name, email or medical details are requested. Daily network codes help prevent spam; hosting may process technical information. This is not a promise of anonymity. Privacy details.

Enable JavaScript to send feedback.

Suggest a missing topic or describe a correction. Please keep personal medical information out of website feedback.

Back to top